it has reportedly also been used in birth control pills ohpa is a progestin or a synthetic progestogen and hence is an agonist of the progesterone receptor the biological target of progestogens like progesterone ohpa was discovered in 1953 and was introduced for medical use in 1956 ohpa has been used in the treatment of a variety of gynecological disorders including secondary amenorrhea functional uterine bleeding infertility habitual abortion dysmenorrhea and premenstrual syndrome ohpa 100 mg was reportedly marketed in combination with mestranol 80 g as a sequential combined birth control pill under the brand name hormolidin the preparation was available in the early 1970s the firm that manufactured it known as gador was based in argentina ohpa is a progestogen and acts as an agonist of the progesterone receptor pr both pr and pr isoforms ic 16 8 nm and 12 6 nm respectively it has more than 50 fold higher affinity for the pr isoforms than 17 hydroxyprogesterone a little less than half the affinity of progesterone and slightly higher affinity than ohpc additional studies have reported on the affinity of ohpa for the pr ohpa is of relatively low potency as a progestogen which may explain its